A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease after it virtually cured every member of a clinical trial. Dostarlimab, a monoclonal antibody drug that is already approved to treat endometrial cancer in the UK, smashed expectations in a recent trial at Memorial Sloan Kettering Cancer Center in New York. One year after the trial ended, each of the 18 participants' ...